We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Precise Ion Irradiation Dosing Method Developed for Cancer Therapy

By LabMedica International staff writers
Posted on 31 Jul 2014
Scientists are employing nuclear physics principles to provide more effective approaches to radiotherapy treatment for cancer patients.

Radiation therapy using heavy ions is best suitable for cancer patients with tumors that are difficult to access, such as in the brain. More...
These particles scarcely damage the penetrated tissue around the tumor, and can be used in such a way that they deliver their maximum energy only directly at their intended target: the tumor.

New research in this comparatively new technology is concentrated on the exact dosing: the investigators must figure out how precisely to set the radiation parameters to destroy the cancerous cells directly with as little damage as possible to the surrounding tissue. The solution depends on the extent to which the ions can be decelerated by body tissue on their way to the tumor.

Scientists from the Physikalisch-Technische Bundesanstalt (PTB; Braunschweig, Germany) have established a strategy for the more precise determination of the deceleration of carbon ions in the tissue in the therapeutically relevant area, which is totally a new approach. Although the measurement data available up to now must still become more exact, the technique has been show to perform well and can, in the future, contribute to improving the dosing for cancer therapy with carbon ions. The first findings of this research have been published June 13, 2014, in the journal Physics in Medicine and Biology.

Human tissue mostly consists of water. It can, therefore, be simulated in liquid water in which form accelerated ions can be blocked on their way and at which target they deliver their maximum energy quantity—at least hypothetically, because up to now research findings have existed only for water vapor. Scientists, however, assume that if the aggregate state is neglected, the data for the determination of the radiation dose become too imprecise.

PTB scientists have now succeeded for the first time in determining the decelerating power of liquid water for carbon ions with kinetic energies in the range of the maximum energy dissipation by experiment. These findings indicate that carbon ions are less strongly blocked in liquid water, per molecule, than in water vapor. As soon as more definitive data become available, the findings will include the calibration of ionization chambers, which are used to determine the dose in therapy planning. Currently, the Heidelberg Ion-Beam Therapy Center (HIT; Germany) is the only institution in Europe that irradiates patients with heavy ions.

The procedure applied by the researchers is based on a method that originates from nuclear physics: the inverted Doppler shift attenuation technique. While the carbon ions excited by a nuclear reaction move through the water volume, they are stopped and fall back into their ground state. The energy distribution of the gamma quanta emitted thereby is recorded with the aid of an ultra-pure germanium detector. The Doppler Effect, which leads to the displacement of the gamma energy, and the exponential-decay principle allow for the development of the velocity of the carbon ions with time to be studied, and therefore, conclusions about the stopping process can be drawn, according to the researchers.

Related Links:

Physikalisch-Technische Bundesanstalt
Heidelberg Ion-Beam Therapy Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Drug Testing Assays
Atellica DT 250 Analyzer
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image: MPNST is a cancer of the connective tissue surrounding peripheral nerves, with NF1 being a key risk factor (Image Credit: Nephron/Wikimedia Commons (CC BY-SA 3.0)

Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors

Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.